Ami Organics makes a strong debut, shares list at 48% premium

Specialty chemicals company Ami Organics made a strong debut on the bourses, listing at a 48 premium against its IPO price of Rs 610 a share on September 14.
On the BSE, the stock debuted at Rs 902, up 47.87%, while it opened 49.18% higher at Rs 910 on the National Stock Exchange.
The listing was better than analysts’ expectations following a strong response the public offer. The initial public offering was subscribed 64.54 times during September 1-3, 2021, as investors bid for 42.22 crore shares against the offer size of 65.42 lakh shares.

The portion reserved for qualified institutional buyers and non-institutional investors was subscribed 154.81 times and 86.64 times, respectively. Retail portion was subscribed 13.36 times.
The company mopped up Rs 570 crore through its public offer that comprised a fresh issue of Rs 200 crore and an offer for sale of Rs 370 crore by shareholders.
The company plans to use fresh issue and pre-IPO placement funds for repaying debts and meeting working capital requirements.

Ami Organics makes specialty chemicals with varied end usage, focussed on the development and manufacturing of pharma intermediates for regulated and generic active pharmaceutical ingredients, new chemical entities and key starting material for agrochemical and fine chemicals.
Ami Organics earned more than half of its revenue from overseas markets with exports contributing 51.5% to its revenues in FY21.
The pharma intermediates manufactured by the company are used in anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, antidepressant and anti-coagulant drugs. The company supplies to more than 25 countries, and has over 150 customers in India.

Disclaimer –
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.